Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
Venture investors keep the purse strings tight
Third-quarter numbers show that biopharma venture investments are firmly back in 2018 territory.
Trad device start-ups catch the cash
Young device makers were surprisingly appealing to VCs in the first half of 2022 – unless they were active in digital health.
Corporate venture investors stay strong
The big names in biotech venture investment might be pulling back, but funds backed by pharma are still out there.
Venture financing holds steady for device makers
Medtech VCs have plenty of cash, which is just as well because the IPO window is shut and locked.
The retrenchment begins for venture funding
The gloomy climate for biotech is now taking its toll on private companies too.
In 2021 it paid to stay private when the chips were down
While biotech indices fell, 2021 saw private companies raise the largest amount of venture capital ever.
